- Home
- AMIX vs CYCN Comparison
AMIX vs CYCN Comparison
Compare AMIX & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- CYCN
- Stock Information
- Founded
- AMIX 2014
- CYCN 2018
- Country
- AMIX United States
- CYCN United States
- Employees
- AMIX N/A
- CYCN N/A
- Industry
- AMIX
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- AMIX
- CYCN Health Care
- Exchange
- AMIX NYSE
- CYCN Nasdaq
- Market Cap
- AMIX 5.5M
- CYCN 6.5M
- IPO Year
- AMIX N/A
- CYCN N/A
- Fundamental
- Price
- AMIX $1.97
- CYCN $3.01
- Analyst Decision
- AMIX
- CYCN
- Analyst Count
- AMIX 0
- CYCN 0
- Target Price
- AMIX N/A
- CYCN N/A
- AVG Volume (30 Days)
- AMIX 13.5K
- CYCN 12.7K
- Earning Date
- AMIX 05-30-2025
- CYCN 05-06-2025
- Dividend Yield
- AMIX N/A
- CYCN N/A
- EPS Growth
- AMIX N/A
- CYCN N/A
- EPS
- AMIX N/A
- CYCN N/A
- Revenue
- AMIX N/A
- CYCN $2,000,000.00
- Revenue This Year
- AMIX N/A
- CYCN N/A
- Revenue Next Year
- AMIX N/A
- CYCN N/A
- P/E Ratio
- AMIX N/A
- CYCN N/A
- Revenue Growth
- AMIX N/A
- CYCN N/A
- 52 Week Low
- AMIX $1.52
- CYCN $1.27
- 52 Week High
- AMIX $75.80
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- AMIX 53.21
- CYCN 61.70
- Support Level
- AMIX $1.61
- CYCN $2.44
- Resistance Level
- AMIX $2.06
- CYCN $2.75
- Average True Range (ATR)
- AMIX 0.11
- CYCN 0.19
- MACD
- AMIX 0.07
- CYCN 0.06
- Stochastic Oscillator
- AMIX 82.59
- CYCN 95.31
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.